Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Joinn Laboratories (China) Co's Revenue for the
three
months ended in Jun. 2026 was ¥388 Mil. Joinn Laboratories (China) Co's average Accounts Receivable for the
three
months ended in Jun. 2026 was ¥176 Mil.
Hence, Joinn Laboratories (China) Co's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.20.
Joinn Laboratories (China) Co (SHSE:603127) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Joinn Laboratories (China) Co Receivables Turnover Related Terms
Joinn Laboratories (China) Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co Receivables Turnover Chart
SHSE:603127 vs TMO, DHR, NTRA: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (SHSE:603127) has a Receivables Turnover of 2.20 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Joinn Laboratories (China) Co and its competitors. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #32 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 15.8%.
Is Joinn Laboratories (China) Co's Receivables Turnover too high?
Joinn Laboratories (China) Co's current Receivables Turnover is 2.20. The Medical Diagnostics & Research industry median Receivables Turnover is 5.40. Joinn Laboratories (China) Co's value of 2.20 is 59.2% below this industry median. Based on the distribution chart, Joinn Laboratories (China) Co ranks #32 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Joinn Laboratories (China) Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #32 out of 202 companies for Receivables Turnover. This places Joinn Laboratories (China) Co in the top 16% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.40. Joinn Laboratories (China) Co's value of 2.20 is 59.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.40, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joinn Laboratories (China) Co's current Receivables Turnover of 2.20 is 59.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Joinn Laboratories (China) Co and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joinn Laboratories (China) Co's current Receivables Turnover is 2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.00, compared to a current price of ¥42.94 — trading 152.6% above its estimated fair value. The current Receivables Turnover is 2.20 and 59.2% below the Medical Diagnostics & Research industry median of 5.40. Joinn Laboratories (China) Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Receivables Turnover is 2.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥42.94 is trading 152.6% above its estimated GF Value™ of ¥17.00.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
Receivables Turnover: 2.20
GF Value™: ¥17.00 vs. price of ¥42.94 (152.6% above fair value)
Industry Position: 59.2% below the Medical Diagnostics & Research median (#32 of 202)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
71GF Score
Get the complete analysis for SHSE:603127
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
